Loading organizations...
Tenyall & Sumin is an investment management firm specializing in pharmaceutical and healthcare sectors. It provides equity and M&A advisory to companies developing novel solutions in biomedicine, advanced drug formulation, and emerging fields like brain-computer interfaces, aiming to accelerate growth for medical innovation.
The firm was founded in May 2015 by Mr. Yuan Angen, establishing Nanjing Tenyall Capital Management Co., Ltd. October 2015 saw the formation of Jiangsu Tenyall Hongyou Investment Management Co., Ltd., a specialized platform under Tenyall Capital. Mr. Angen foresaw capitalizing on significant growth within evolving healthcare and pharmaceutical markets.
Tenyall & Sumin partners with emerging and scaling biomedical and healthcare companies. It offers financial backing and strategic collaboration to boost market presence and technological progress. Its guiding vision, "innovate to expand the future," reflects a commitment to nurturing future industry leaders.
Tenyall & Sumin has 1 tracked investment across 1 company. The latest tracked deal is $45.0M Series A in Thousand Oaks Biopharmaceuticals in January 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 3, 2019 | Thousand Oaks Biopharmaceuticals | $45.0M Series A | Liefeng Qu | Blue Bay Capital, Ji Lin Ao Dong, Qianrong Holdings |